Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Don’t miss cardiovascular risk factors in transgender patients

Key clinical point: Transgender individuals may have elevated cardiovascular risk.

Major finding: The incidence of undiagnosed hypertension and hyperlipidemia was 6.8% and 11.3%, respectively, in transgender individuals who had not yet undergone gender-affirming hormone therapy.

Study details: The data come from a retrospective study of 427 transgender persons seeking gender-affirming hormone therapy.

Disclosures: The study received no outside funding. Lead author Dr. Denby had no financial conflicts to disclose.

Citation:

Denby KJ et al. AHA 2020, Presentation P2274.